Kodiak Sciences (NASDAQ:KOD) Rating Increased to Hold at Wall Street Zen

Posted by Stanley Muller on May 17th, 2026

Wall Street Zen upgraded shares of Kodiak Sciences (NASDAQ:KOD – Free Report) from a sell rating to a hold rating in a research note published on Saturday morning.

Other research analysts also recently issued reports about the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Kodiak Sciences in a research note on Thursday, January 22nd. HC Wainwright reaffirmed a “buy” rating and set a $58.00 price target (up from $38.00) on shares of Kodiak Sciences in a research note on Friday, March 27th. UBS Group upped their price target on Kodiak Sciences from $50.00 to $80.00 and gave the stock a “buy” rating in a research note on Friday, March 27th. Finally, Chardan Capital raised Kodiak Sciences from a “neutral” rating to a “buy” rating and upped their price target for the stock from $14.00 to $61.00 in a research note on Monday, May 11th. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $42.14.

Read Our Latest Report on KOD

Kodiak Sciences Trading Down 4.3%

Shares of KOD opened at $37.02 on Friday. The company has a market capitalization of $2.32 billion, a PE ratio of -8.88 and a beta of 2.32. Kodiak Sciences has a 12 month low of $3.13 and a 12 month high of $47.84. The stock’s 50-day moving average price is $36.42 and its two-hundred day moving average price is $28.43.

Kodiak Sciences (NASDAQ:KOD – Get Free Report) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.94) earnings per share for the quarter, missing the consensus estimate of ($0.93) by ($0.01). Equities research analysts predict that Kodiak Sciences will post -3.89 EPS for the current fiscal year.

Institutional Trading of Kodiak Sciences

Institutional investors and hedge funds have recently modified their holdings of the business. Westfuller Advisors LLC bought a new position in Kodiak Sciences during the first quarter valued at $26,000. V Square Quantitative Management LLC bought a new position in Kodiak Sciences during the first quarter valued at $26,000. EverSource Wealth Advisors LLC grew its holdings in Kodiak Sciences by 1,221.3% during the fourth quarter. EverSource Wealth Advisors LLC now owns 991 shares of the company’s stock valued at $28,000 after purchasing an additional 916 shares during the period. KBC Group NV bought a new position in Kodiak Sciences during the first quarter valued at $39,000. Finally, GF Fund Management CO. LTD. bought a new position in Kodiak Sciences during the fourth quarter valued at $29,000. 89.06% of the stock is owned by hedge funds and other institutional investors.

About Kodiak Sciences

(Get Free Report)

Kodiak Sciences, Inc is a clinical‐stage biopharmaceutical company headquartered in Palo Alto, California, that focuses on the discovery and development of novel therapies for retinal diseases. The company’s proprietary technology centers on antibody biopolymer conjugates (ABCs), which are designed to extend durability, enhance tissue penetration and improve the safety profile of existing therapeutic modalities. Kodiak’s research and development efforts target conditions such as wet age-related macular degeneration (wet AMD), diabetic macular edema (DME) and other serious ophthalmic disorders.

The lead product candidate in Kodiak’s pipeline is KSI-301, an anti-VEGF antibody biopolymer conjugate administered via intravitreal injection.